Keystone Nano Tests Promising New Cancer Treatments


Keystone Nano, a State College-based biopharmaceutical company, is developing new treatments in the fight against cancer and its new, potentially ground-breaking therapies could be available sooner rather than later.

The company is currently developing three different approaches to cancer therapy with products that address liver cancer, leukemia, and breast cancer.

Its lead product, Ceramide NanoLiposome (CNL), is expected to enter the human clinical trial in mid-2016 for liver cancer. Prior trials have shown tumor regression and disease free survival in liver cancer models. Meanwhile, their second product, PINT-Leukemia, is ready for pre-clinical development and can enter the clinic in 18 to 24 months.

The third product platform, siRNA-NanoJackets, is supported by recent grants from National Cancer Institute for oncology and National Institute of Allergy and Infectious Diseases (NIAID) for infectious disease. It is expected to be ready for pre-clinical development in 12 to 18 months. Testing so far has shown a 95% and 97% target protein knockdown in breast cancer models.